Selectis Health Corporation (OTCMKTS: GBCS) is a U.S.-based specialty healthcare company focused on the research, development and commercialization of proprietary medical technologies and consumer health products. The company develops and markets advanced wound care dressings, orthopedic regenerative implants and novel nutraceutical formulations. Selectis Health’s product portfolio includes scaffold-based healing matrices, bioactive joint support supplements and a range of topical and oral therapeutic agents designed to support tissue regeneration and overall wellness.
Founded in 2012 and headquartered in Miami, Florida, Selectis Health has expanded its operations to serve key markets across North America, Europe and Asia. The company’s manufacturing facilities adhere to current Good Manufacturing Practice (cGMP) standards, and it leverages strategic partnerships to enhance its supply chain, distribution network and regulatory compliance. Over the years, Selectis Health has secured several patents and trademarks for its proprietary biomaterials and delivery systems.
In addition to its core product lines, Selectis Health operates a research and development center focused on emerging regenerative medicine applications, including cellular therapies and 3D-bioprinting technologies. The company’s R&D pipeline encompasses next-generation wound closure devices, orthopedic cartilage scaffolds and synergies with digital health platforms for remote patient monitoring. Selectis Health also offers contract manufacturing services for select partners seeking cGMP-certified production of medical-grade products.
Selectis Health is led by a management team with deep industry experience. John P. Richards serves as President and Chief Executive Officer, bringing over 25 years of leadership in medical device commercialization. Chief Scientific Officer Dr. Maria L. Ortega oversees the company’s R&D efforts, while Chief Financial Officer Peter Zhao manages financial planning and investor relations. The board includes a mix of healthcare veterans and life sciences investors, positioning the company for strategic growth as it advances its product pipeline.
AI Generated. May Contain Errors.